STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy.
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Jan 2018
At a glance
- Drugs IXT-m200 (Primary)
- Indications Drug abuse
- Focus Pharmacokinetics; Proof of concept
- Acronyms STAMPOUT
- Sponsors InterveXion Therapeutics
- 04 Jan 2018 According to an InterveXion Therapeutics media release, the company recently announced full US NIDA funding for this upcoming Phase 2 study which is expected to initiate in 1H18.
- 06 Nov 2017 Status changed from planning to not yet recruiting.
- 11 Oct 2017 New trial record